You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Long non coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases

    SBC: IQuity Labs, Inc.            Topic: NIAID

    No other group of diseases encompasses a greater pathophysiology than do the rheumatic diseases Spanning multiple organ systems clinical decisions often rely on coordinated efforts from primary care providers and rheumatologists to rule in or rule out differential diagnoses when treating inflammatory conditions such as rheumatoid arthritis RA and systemic lupus erythematosus SLE RA is a sym ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. New Technologies for Therapist Training and Patient Engagement in Behavioral Parent Training

    SBC: KOBAK, KENNETH A            Topic: 104

    Project Summary Abstract Behavioral parent trainingBPTis the gold standard treatment for disruptive behavior in preschool and elementary school age childrenDespite clear empirical evidence that it is effectiveadoption rates by practitioners remains woefully low due in part to a shortage of clinicians trained in BPTIn additioneven when BPT is administeredit is often done incorrectlyThe current stud ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical Evaluation of Ancestral Coagulation Factor VIII

    SBC: EXPRESSION THERAPEUTICS, LLC            Topic: NHLBI

    ABSTRACT The development of transformative therapeutics including the possibility of a cure though gene therapy is the sole mission of Expression Therapeutics and continues to be a major research and development activity in the overall $ B USD hemophilia market space However progress in the field has been limited by significant hurdles including the size complexity instability immunogenic ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Biomaterials for mRNA based cellular reprogramming

    SBC: STEM PHARM, INCORPORATED            Topic: 100

    Project Summary Abstract Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and regenerative medicine and as a result have unique commercial potential There are currently more than ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC derived retinal pigment epithelial cells to treat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. OpenBeds: Improving the Delivery of Care for Patients with Drug Addiction

    SBC: Openbeds Inc.            Topic: NIDA

    There is an urgent need for more effective mechanisms that leverage current technologies and best practices to both identify capacity and refer patients to drug treatment facilitiesThe applicant organizationOpenBeds Incis partnering with the non profit MESH Coalitionthree of the largest health care systems offering drug treatment in Indiana and the Indiana Division of Mental Health and AddictionDM ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Media based youth e cig prevention toolkit for community based organizations

    SBC: KDH Research & Communication, Inc.            Topic: NIDA

    KDH Research andamp Communication KDHRC submits this Fast Track SBIR proposal to develop and evaluate AVOID Anti Vaping Online Information Dissemination a media based online toolkit to support community based organizations CBO prevention programming against youth e cigarette e cig use Youth e cig use also known as vaping is a rapidly growing public health threat with use among hi ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E coli strains

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    Scarab Genomics goal is to commercialize carrier proteins for conjugate vaccine manufacture This proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in use in pre clinical and clinical studies Exoprotein A EPA from Pseudomonas aeruginosa and Protein D PD from non typeable Haemophilus influenzae These proteins are difficult to make by the conve ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Novel sanitizer against viral infections with long lasting effect

    SBC: CAMELLIX, LLC            Topic: NIAID

    Project Summary Abstract Despite mandatory use of hand sanitizer on cruise ships there are reported cruise ship onboard norovirus outbreaks in exceeded the number of norovirus outbreaks outbreaks onboard cruise ships in One of the problems of currently available alcohol based hand sanitizer is that alcohol evaporates in less than seconds after each application to a surface ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Anti CCL mAb to treat castration resistant prostate cancer

    SBC: JYANT Technologies, Inc.            Topic: 102

    Metastatic castration resistant prostate cancer CRPC PCa accounts for of PCa deaths and is associated with skeletal metastases CRPC affects patients differently making this disease difficult for physicians to provide standardized treatments with similar outcomes Docetaxel can prolong the overall survival in patients with metastatic CRPC but current therapies do not provide a cure Doce ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Advanced PML antiviral

    SBC: Inhibikase Therapeutics, Inc.            Topic: NIAID

    Inhibikase Therapeutics is a clinical stagebiopharmaceutical company that has developed a hosttargeted mechanism of action to treat AIDS related and drug induced progressive multifocal leukoencephalopathyPMLPML is a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the midsDuring the height of the epidemicthe rate of PML o ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government